Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2024-03-14 Earnings Release
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (LegoChem Biosciences) announcing a significant change (over 30%) in revenue or profit structure. This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial shifts before the final audited annual report is finalized. It provides key financial highlights and reasons for the variance, fitting the definition of an Earnings Release (ER) as it serves as an initial announcement of financial performance metrics. FY 2023
2024-03-14 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for LegoChem Biosciences. It contains the meeting agenda, details on board elections, financial reporting, and governance information. In the context of financial filings, a document that serves as the formal notice and proxy materials for an upcoming shareholder meeting is classified as a Proxy Solicitation & Information Statement (PSI).
2024-03-14 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for LegoChem Biosciences. It details the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of upcoming meeting details and to request their votes on specific agenda items.
2024-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date that coincides with other companies' meetings. Since it is a regulatory announcement regarding meeting logistics rather than the meeting materials themselves, proxy statements, or voting results, it falls under the general regulatory filing category.
2024-03-12 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 100% confidence The document is a regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the resignation of an outside director (사외이사). This falls under the category of changes in board or management personnel.
2024-01-25 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, time, location (online Zoom link), purpose, and agenda (Orion third-party capital increase). Since this is an announcement of an event rather than the presentation slides themselves, and it is a regulatory disclosure of an IR event, it fits the definition of a Regulatory Filing (RNS) or a general announcement of corporate activity.
2024-01-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.